Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 3 Nasopharyngeal Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hypopharyngeal Neoplasms 1 Hematologic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Gastric Cancer 1 Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 240 Rituximab 187 fludarabine phosphate 129 Etoposide 110 Peripheral Blood Stem Cell Transplantation 108 Mycophenolic Acid 94 Filgrastim 91 Melphalan 90 Whole-Body Irradiation 88 fludarabine 80 Busulfan 80 Tacrolimus 71 Cytarabine 66 Cyclosporine 66 Radiotherapy 62 Methotrexate 53 Antilymphocyte Serum 53 Granulocyte Colony-Stimulating Factor 51 Vincristine 49 Carmustine 48 Doxorubicin 41 Prednisone 37 Thiotepa 33 Bendamustine Hydrochloride 32 Bortezomib 30 Methylprednisolone 29 Dexamethasone 28 Stem Cell Transplantation 27 thymoglobulin 26 ibritumomab tiuxetan 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma, Non-Hodgkin × CF regimen × Clear all

NCT05370547 2024-03-06

Chidamide Bridging for CAR-T Therapy

Chinese PLA General Hospital

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡